Guardant Wins Prix Galien Award for Shield Test
The colorectal cancer blood test was named the top medical technology innovation at the 2026 Prix Galien USA Awards.
Updated on Nov. 3, 2026 in Cancer
Live Poll
Have you completed a colorectal cancer screening, or do you plan to get one?
Guardant Health won the 2026 Prix Galien USA Award for Best Medical Technology for Shield, a blood test for detecting colorectal cancer. The award was selected by a panel of science leaders, Nobel laureates, and industry executives across eight award categories.
Why it matters
Shield became the first blood test to receive FDA approval for primary colorectal cancer screening in 2024 and is included in American Cancer Society and National Comprehensive Cancer Network guidelines. The recognition highlights a growing shift toward noninvasive screening options for a disease that is commonly screened for in the United States.
Clinical trials reported 100% sensitivity for detecting stage 2-4 colorectal cancer and 98.5% specificity for Shield. More than 200,000 tests have been performed in real-world settings, with completion rates above 90%, though the trial comparator and population were not specified.
The players
Guardant Health
Guardant Health is a precision oncology company that develops liquid biopsy tests, including the Shield colorectal cancer screening blood test.
Prix Galien USA Awards
The Prix Galien USA Awards are annual honors recognizing innovation in pharmaceuticals and medical technology, often regarded as a leading prize in the life sciences industry.
The details
Shield is a blood-based colorectal cancer detection test that was selected as the top innovation in the medical technology category at the Prix Galien USA Awards. The award is one of eight categories honored by the annual program.
Timeline
2024: Shield received FDA approval for primary colorectal cancer screening.
Beginning of 2025: Guardant secured Medicare coverage for its blood test to monitor for disease recurrence in colorectal cancer patients.
2026: Shield won the Prix Galien USA Award for Best Medical Technology.
Health Landscape
Shield's 2024 FDA approval as the first blood test for primary colorectal cancer screening marked a departure from stool-based and colonoscopy-centered screening pathways. The 2026 award recognizes the test's growing adoption within American Cancer Society and National Comprehensive Cancer Network guidance.
Shield offers a noninvasive blood-based option for colorectal cancer screening that patients may discuss with their clinicians as an alternative to stool or colonoscopy-based methods. The test is covered by Medicare for recurrence monitoring in patients already diagnosed with colorectal cancer.
The takeaway
Screening options for colorectal cancer are expanding beyond traditional methods, and patients should ask their clinicians which approach fits their situation. Tests with high reported sensitivity still require follow-up discussion about results and next steps.
Further reading
Explore more cancer screening and detection coverage on Wisevoter for context on how new tests fit into national prevention efforts.
Source note: This article includes information reported by MDDI Online.
Live Poll
Have you completed a colorectal cancer screening, or do you plan to get one?
